Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHSE: 600276)
Health Care · Pharmaceuticals · CN
CN¥46.85
-0.34% today · -34.2% 1Y
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHSE: 600276) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.07B and employs 20,602 people.
Over the last twelve months the share price has lost 34.2%, trading between 41.89 and 71.66.
Tweenvest scores Jiangsu Hengrui Pharmaceuticals Co.,Ltd across four factors: quality 79/100, value 65/100, growth 82/100, dividend 45/100. Its strongest factor is growth.
600276 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.07B
- Revenue (TTM)
- $4.61B
- P/E
- 40.26
- EPS
- 1.16
- Dividend yield
- 0.43%
- Beta (5Y)
- 0.05
- 52-week high
- CN¥71.66
- 52-week low
- CN¥41.89
- Avg volume (3M)
- —
- Shares outstanding
- 6.62B
- Employees
- 20,602
- Next earnings
- —
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
- ISIN
- CNE0000014W7
- Founded
- 1970
- Listed since
- Oct 18, 2000
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Takeda Pharmaceutical Company LimitedTSE: 4502 | $58.92B | ¥5,843.00 | +0.46% |
| Bayer AktiengesellschaftXTRA: BAYN | $48.15B | €43.73 | -0.09% |
| Teva Pharmaceutical Industries LimitedNYSE: TEVA | $47.89B | $41.37 | +0.66% |
| Galderma Group AGSWX: GALD | $46.30B | CHF168.65 | +2.24% |
| Sun Pharmaceutical Industries LimitedNSEI: SUNPHARMA | $43.63B | Rs1,760.00 | +0.01% |
| UCB SAENXTBR: UCB | $43.44B | €204.00 | +0.25% |
| Haleon plcLSE: HLN | $40.71B | £3.49 | +1.42% |
| Otsuka Holdings Co., Ltd.TSE: 4578 | $38.71B | ¥11,665.00 | -0.13% |
Figures last refreshed Oct 11, 2026.